Biocon extends licensing pact with Equillium for itolizumab

Itolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand name ALZUMAb to treat moderate to severe plaque psoriasis, a skin disease.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Kharawala S, Golembesky AK, Bohn RL, Esser D Abstract Introduction: Generalized pustular psoriasis (GPP) is characterized by widespread erythema and edema, superficial sterile coalescing pustules, and lakes of pus. Although the impact of GPP is thought to be substantial, emerging literature on its clinical, humanistic, and economic burden has not previously been described in a structured way.Areas covered: A structured search focused on the identification of studies in GPP using specific search terms in PubMed and EMBASE® from 2005 onwards, with additional back-referencing and pragmatic searches. Outco...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
Condition:   Plaque Psoriasis Intervention:   Drug: ARQ-151- cream 0.3% Sponsor:   Arcutis Biotherapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Psoriasis;   Psoriatic Arthritis Intervention:   Diagnostic Test: Questionary Sponsor:   Bezmialem Vakif University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Plaque Psoriasis Intervention:   Drug: ARQ-151- cream 0.3% Sponsor:   Arcutis Biotherapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: Lichen Planus Severity Index is a new reproducible tool to grade the severity of lichen planus.
Source: Indian Journal of Dermatology, Venereology and Leprology - Category: Dermatology Authors: Source Type: research
Priyanka Gowda, Veeranna Shastry, P. S. S. Ranugha, Vinutha RangappaIndian Journal of Dermatology, Venereology, and Leprology 2020 86(2):231-231
Source: Indian Journal of Dermatology, Venereology and Leprology - Category: Dermatology Authors: Source Type: research
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Psoriasis, a chronic immune-mediated disease, is associated with an increased risk of cardiovascular events and mortality. Secukinumab selectively neutralizes IL-17A and has demonstrated high efficacy with a favorable safety profile in various psoriatic disease manifestations.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
Conditions:   Mesenchymal Stromal Cells;   Psoriasis;   Drug Effect;   Drug Toxicity Interventions:   Drug: Calcipotriol ointment;   Drug: PSORI-CM01 Granule;   Biological: adipose-derived multipotent mesenchymal stem cells Sponsor:   Guangdong Provincial Hospital of Traditional Chinese Medicine Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Rheumatoid Arthritis;   Psoriasis Interventions:   Other: Harkány medicinal water;   Other: Tap water (placebo control) Sponsors:   University of Pecs;   National Research, Development and Innovation Office, Hungary;   Harkány Spa Hospital, Hungary Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | India Health | Pharmaceuticals | Psoriasis | Skin